|
| Author [reference] | Pts
| Median Age (y) | FIGO stage
(%) | Grade
(%) | Histology
(%) | Relapse rate
(%) | Mean PFS (mo) or 5 y DFS | Characteristics of pts who relapsed | 5 y OS | Death | LND |
|
| Kwon et al. 2009 [18] | 21 | 26.7 | 17 (81%) IA
4 (19%) IC
| 16 (76%) G1
3 (14%) G2
2 (9.5%) G3 | 16 (76%) muc
2 (9.5%) endom
2 (9.5%) clear cell
1 (4.7%) serous | 1 (4.7%) | 34 | IC, muc | NR | NR | Yes |
| Kajiyama et al. 2008 [19] | 10 | 35.9 | 4 (40%) IA
6 (60%) IC
| NR | 10 (100%) clear cell | 1 (10%) | 33 | IC, G2,
clear cell | NR | 1 (10%) | Optional |
| Schlaerth et al. 2009 [3] | 20 | 27 | 11 (55%) IA
9 (45%) IC
| 14 (70%) G1
5 (25%) G2
1 (5%) G3 | 11 (55%) muc
1 (5%) serous
6 (30%) endom
1 (5%) clear cell | 3 (15%) | 4.3
(9–22) | 2 IC,
1 IA | 84% | 3 (15%) | Yes |
| Borgfeldt et al. 2007 [20] | 11 | NO | IA
IC | G1
G3 | NR | 1 (9%) | NR | IC, G3 | NR | NR | Yes |
| Schilder et al. 2002 [11] | 52 | 26 | 42 (81%) IA
10 (19%) IC
| 38 (73%) G1
9 (17%) G2
5 (9.6%) G3 | 25 (48%) muc
10 (19%) serous
5 (9.6%) clear cell
2 (4%) mixed | 5 (9.6%) | 14
(8–78) | 4 IA, G1
1 IC, G2
2 muc
2 serous
1 endom | 98% | 2 (4%) | Yes |
| Kajiyama et al. 2011 [21] | 74 | <40 | 36 (48%) Ia
1 (1.3%) Ib
37 (50%) Ic | 57 (77%)
G1/G2
4 (5.4%) G3 | 4 (5.4%) serous
43 (58%) muc
13 (18%) clear cell
4 (5.4%) endom | NR | 87.9%
5 y DFS | NR | 90.8% | 2 (2.7%) | Yes |
| Zanetta et al. 1997 [12] | 56 | 29 | 32 (57%) : IA
2 (3.5%) : IB
22 (39%) : IC | 35 (62%) G1
14 (25%) G2
7 (12%) G3 | 18 (32%) serous
23 (41%) muc
13 (23%) endom | 5 (9%) | NR | 2 IA,G2, endom
1 IA, G3, muc
1 IA, G1, serous
1 IC, G2, serous | NR | 4 (7%) | Yes |
| Satoh et al. 2010 [16] | 211 | 29 | 126 (60%) IA
85 (40%) IC
| G1: 160 (76%)
G2: 15 (7%)
G3 6 (2.8%)
clear cell: 30 (14.2%) | 126 (60%) muc
27 (13%) serous
27 (13%) endom
30 (14.2%) Clear cell | 18 (8.5%) | 33.3–100% 5 y DFS | Mostly
Ic,G3
Ia, G3
Ic, clear cell
| 66.7–100% | 5 (2.4%) | Yes |
| Kajiyama et al. 2011 [13] | 41 | <40 y | 27 (66%) : IA
14 (34%) : IC | NR | 100% muc
| 3 (7.3%) | 90.5% | | 97.3% | 1 (2.5%) | Yes |
| Kajiyama et al. 2011 [22] | 80 | 35 | 40 (50%) IA
40 (50%) IC | — | 45 (56%) muc
3 (3.75%)serous
15 (19%) endom
16 (20%) clear cell | 10 (12.5%) | 85.5%–92.9% 5 y DFS | 2: IA
8: IC
| 89.3%– 90.5% | 0 | Yes |
| Kajiyama et al. 2010 [23] | 60 | 30 | IA 30 (50%)
IB 1 (1.7%)
IC 29 (48%) | 41 (68%) G1
7 (12%) G2
2 (3.3%) G3 | Serous 5 (8.3%)
Muc. 34 (56.7%)
Endom 11 (18 %)
Clear cell 10 (17%) | 8 (13%) | 89.8% | 2 IA, 1 IB
5 IC | 89.8% | 0 | |
|
| Total | 580 | 26–35.9 | 333 (57%) IA
4 (0.7%) IB
234 (40%) IC | 334 (57%) G1
39 (6.7%) G2
20 (3.4%) G3 | 300 (52%) muc
51 (9%) serous
128 (22%) clear cell
65 (11%) endom | 50 (8.6%) | 33.3–100%
5 y DFS | | 66.7–100% | 18 (3.1%) | Yes |
|
